| Document |
Document Title |
|
WO/2023/013786A1 |
Provided is a nucleic acid structure that enhances an antigen-specific immune response. The nucleic acid structure includes a polynucleotide that codes for a SNARE protein, a polynucleotide that codes for a proprotein convertase recognit...
|
|
WO/2023/013787A1 |
Provided is a nucleic acid structure that enhances an allergen-specific immune response. The nucleic acid structure includes a polynucleotide that codes for a SNARE protein and a polynucleotide that codes for an allergen.
|
|
WO/2023/007430A1 |
The invention relates to compounds of general formula (I): for use in the prevention and/or treatment of infectious diseases.
|
|
WO/2023/007409A1 |
This invention relates to a chimaeric BLV-Gag VLP which contains T. parva p67 and/or gp34 antigens on its surface, the invention also relates to vectors comprising nucleic acids encoding the BLV-Gag proteins; and T. parva p67 and/or T. p...
|
|
WO/2023/004427A1 |
Methods of treating severe and uncomplicated malaria comprising administering an isoform of artemisinin, a hydrophobic amine, and a spleen tyrosine kinase (Syk) inhibitor. Further provided is a unitary, oral dosage form comprising an iso...
|
|
WO/2023/002965A1 |
This salt of the compound represented by formula (I) and crystals thereof are applicable as an active pharmaceutical ingredient of pharmaceutical products.
|
|
WO/2023/001893A1 |
The present disclosure relates specifically to novel glutarate salt forms of Ulodesine or the compound known as 7-[(3R, 4R)-3-Hydroxy-4-hydroxymethyl-pyrrolidin-1ylmethyl] -3, 5-dihydro-pyrrolo [3,2-d]pyrimidin-4-one and methods of prepa...
|
|
WO/2023/272370A1 |
The present invention relates to a veterinary vaccine composition based on fatty-acid-binding proteins (FABP) from parasites. Specifically, the invention discloses a veterinary vaccine composition based on the Schistosoma mansoni protein...
|
|
WO/2023/275537A1 |
The present invention relates to compounds of formula (I) and formula (II). The compounds of the invention may be used in a method of treatment of a fungal infection, a bacterial infection, or an ameobic infection.
|
|
WO/2023/272362A1 |
The present invention relates to the field of oral delivery of therapeutic compounds to fish through fish feed additives, including aquatic animal feed additive compositions and methods of treating or preventing diseases in aquatic animals.
|
|
WO/2022/268648A1 |
The present invention relates to compounds of formula I wherein Q is as pesticides for combating and controlling insects, acarines, nematodes or molluscs. An exemplary compound is e.g. 2-[3-[l[[6-chloro-8-(trifluoromethyl) quinazolin-4-y...
|
|
WO/2022/270459A1 |
The present invention pertains to a therapeutic medicine for dysentery amebiasis that contains a compound represented by formula (I) (wherein R1, R2, R3, R4, R5, R6, R7 and R8 are the same or different and represent a hydrogen atom, a ha...
|
|
WO/2022/267983A1 |
Provided are an engineered immune cell and a use thereof in the treatment of cancer, infections or autoimmune diseases. The engineered immune cell expresses (i) a cell surface molecule that specifically recognizes an antigen, and (ii) on...
|
|
WO/2022/269042A1 |
The present invention is directed to a stable, efficacious and palatable chewable veterinary composition comprising as active ingredient an isoxazoline compound of Formula (I), a stabilized macrocyclic lactone, pyrantel and excipients.
|
|
WO/2022/265031A1 |
The present invention provides a method for treating a feline with a chronic kidney disease, whereby it becomes possible to prevent the progression of the chronic kidney disease in the feline to IRIS stage 4 or renal death or improve an ...
|
|
WO/2022/263354A1 |
Graft polymers, their preparation and use such as in cleaning compositions and agrochemical compositions and those compositions, wherein the graft polymers comprise as polymer backbone (A) a polyalkylene oxide ester polymer with a weight...
|
|
WO/2022/263557A1 |
The present application relates to compounds of Formula (I) or a pharmaceutically acceptable salt thereof, compositions thereof, and their use in the treatment and/or prophylaxis of systemic infections, such as the treatment and/or proph...
|
|
WO/2022/266383A1 |
The present disclosure provides anti-circumsporozoite (CSP) antibodies, compositions comprising such antibodies. Also disclosed are methods of producing the disclosed antibodies and methods of treating or preventing malaria using the same.
|
|
WO/2022/257981A1 |
Provided is a method for killing mites and treating dry-eye syndrome by means of using compounds and salts, stereoisomers and solvates thereof.
|
|
WO/2022/257986A1 |
The present invention relates to the use of a CYP450 inhibitor in inhibiting or killing mites and treating dry eye syndrome. A large number of experiments show that the CYP450 inhibitor can be used for inhibiting and killing mites, can e...
|
|
WO/2022/258797A1 |
The present invention relates to the treatment of parasitic arthropods, especially Hyalomma spp. tick infestations of animals, by using isoxazoline compounds of Formula (I).
|
|
WO/2022/260568A1 |
The present invention relates to a novel mixed glycerol ester composition comprising glycerol ester molecules comprising both valeric acid moieties and lauric acid moieties in the same molecule. The mixed glycerol ester composition can b...
|
|
WO/2022/256284A1 |
Disclosed are compounds of Formula (I), including all geometric and stereoisomers, N-oxides, and salts thereof, wherein R1, R2, R3, A and T are as defined in the disclosure. Also disclosed are compositions containing the compounds of For...
|
|
WO/2022/255461A1 |
The invention of the present application addresses the problem of providing a dirofilariasis prevention agent for animal use that demonstrates excellent effects when administered to a target animal and a usage method for the dirofilarias...
|
|
WO/2022/255460A1 |
The present invention addresses the problem of providing a canine filariasis control agent for animals that exerts excellent efficacy when administered to a target animal, and a method of the use of a canine filariasis control agent in a...
|
|
WO/2022/255399A1 |
The present invention pertains to a compound represented by general formula (I) or a pharmacologically acceptable salt thereof and a pharmaceutical use thereof, for example, a pharmaceutical composition that is to be used for preventing ...
|
|
WO/2022/255463A1 |
The present invention addresses the problem of providing a canine heartworm disease control agent for animals, said agent exhibiting an excellent effect when administered to a target animal, and a method for using a canine heartworm dise...
|
|
WO/2022/255464A1 |
When a dirofilariasis control agent is used for an extended period of time, there is a risk of developing resistance to the agent that one depends on. The present invention addresses the problem of developing and providing a new medical ...
|
|
WO/2022/255462A1 |
The present invention addresses the problem of providing a canine filariasis control agent for animals that exerts excellent efficacy when administered to a target animal, and a method of the use of a canine filariasis control agent in a...
|
|
WO/2022/255465A1 |
Insect pests, etc. still cause significant damage in agricultural and horticultural crop production, etc. Under these circumstances, the present invention addresses the problem of developing and providing a novel agricultural and horticu...
|
|
WO/2022/246526A1 |
The present invention relates to a recombinant chimeric protein containing immunogenic regions from the trans-sialidase (TS) protein and amastigote surface protein-2 (ASP-2) from Trypanosoma cruzi and a composition containing said protei...
|
|
WO/2022/250104A1 |
The present invention relates to: a compound, or a pharmaceutically acceptable salt thereof, that has an antimalarial action and that is useful as an agent for treating or preventing malaria; and a pharmaceutical composition containing t...
|
|
WO/2022/243877A1 |
a compound of the formula (I), or a pharmaceutically acceptable salt thereof, wherein X, Y, R1, R2, R3, R11, R12, Ra and Rb are as defined therein, and a formulation comprising the same, as well as its use as a medicament and in the trea...
|
|
WO/2022/245950A1 |
Disclosed herein are methods for the treatment of Demodex including the step of contacting the Demodex with 5-fluorouracil, or salt thereof. Disclosed herein are ophthalmic compositions including 5-fluorouracil or salt thereof suitable f...
|
|
WO/2022/241968A1 |
A plant essential oil for the prevention and treatment of coccidiosis, comprising the following components in parts by weight: 0.5-1.3 parts cinnamaldehyde; 0.2-0.7 parts thymol; 0.08-0.3 parts syringol; 0.08-0.3 parts carvacrol; 0.01-0....
|
|
WO/2022/242620A1 |
The present invention provides the following dimeric sesquiterpenoids, a preparation method therefor, and a use thereof. The dimeric sesquiterpenoids have novel chemical structures and remarkable anti-malarial biological activities, have...
|
|
WO/2022/238965A1 |
Described is an anhydrous transdermal formulation comprising one or more active agents, at least 15% by weight terpene hydrocarbon, a veterinary acceptable aprotic solvent, and a veterinary acceptable C2 to C6 volatile solvent having a f...
|
|
WO/2022/241312A1 |
Provided are compositions and methods used for combating ticks and transmission of tick-borne pathogens to tick hosts. The compositions include tick mouthpart protein antigens. The method of using the compositions results in decreased ti...
|
|
WO/2022/239808A1 |
Provided are a compound and an antiparasitic agent that have an antiparasitic activity against zoonotic parasites consisting of protozoa and helminths and are useful for treating or preventing parasitic infections. This antiparasitic age...
|
|
WO/2022/237913A1 |
Disclosed are a limonin compound, a preparation method therefor, and an application of the limonin compound as a drug for treating hydatidosis/echinococcosis, wherein limonin compounds shown in general formulas I, II and III can be effic...
|
|
WO/2022/236370A1 |
The present application is directed to compositions used in vaccinating mammals against erythrocytic organism infection, or treating erythrocytic infection. These compositions comprising erythrocytes and an erythrocytic organism, wherein...
|
|
WO/2022/234069A1 |
This invention relates to 2-aminooxazole derivatives of general formula (I) or a pharmaceutically acceptable salt or solvate thereof wherein Y and Z are two different heteroatoms selected from N and O; X is selected from N and CR12; and ...
|
|
WO/2022/226660A1 |
The present disclosure relates to methods of preventing or treating parasite infection in a plurality of fish in need thereof, comprising administering to the fish an effective amount of an isoxazoline such as fluralaner, a composition c...
|
|
WO/2022/228052A1 |
The use of belinostat or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating infections.
|
|
WO/2022/159581A9 |
The Artemisinin-Proteasome inhibitor conjugate compounds of the present application are represented by the following compounds having Formula (I) where the substituents R1-R5, X, Y, Y', and Z are defined herein. These compounds are used ...
|
|
WO/2022/224924A1 |
The present invention addresses the problem of providing: a nitrogen-containing heteroaryl compound which exhibits excellent bactericidal and anti-bacterial activity and excellent safety and which can be synthesized in an industrially ad...
|
|
WO/2022/223390A1 |
The present invention relates to a method of synthesizing a photolytically degradable compound, which method comprises identifying a biologically active target molecule comprising substituted aromatic group(s); providing a starting mater...
|
|
WO/2022/220669A1 |
The present invention relates to a solid composition with improved stability and bioavailability, which comprises: a pharmaceutically acceptable amount of a macrolide antibiotic agent, a pharmaceutically acceptable amount of an antimalar...
|
|
WO/2022/207793A1 |
The present invention provides vaccines and compositions, methods and uses of immunogenic vaccine compositions for eliciting an immune response to members of trypanosomatids such as Trypanosoma brucei, T. cruzi and Leishmania species.
|
|
WO/2022/200402A1 |
The invention relates to a galenic formulation, suitable for oral administration, comprising a shell containing mini-formulations in solid form, having a size of less than 4.5 mm, of micronized ivermectin, to the method for preparing sam...
|
